Axial Spondyloarthritis (axSpA) Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Axial Spondyloarthritis (axSpA) Market is segmented by Types (Ankylosing spondylitis (AS) and Non-radiographic axial spondyloarthritis (nr-axSpA)), By Drug Class (Non-steroidal anti-inflammatory drugs (NSAID), Glucocorticoids, Anti-rheumatic drugs, and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Axial Spondyloarthritis (axSpA) Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Axial Spondyloarthritis (axSpA) Industry Overview

The axial spondyloarthritis market is fragmented, competitive, and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Johnson & Johnson, UCB, Amgen, Novartis Pharmaceuticals Corporation, Eli Lilly and Company, Kyowa Kirin, AbbVie, Acelyrin, and Pfizer.

Axial Spondyloarthritis (axSpA) Market Leaders

  1. Janssen Biotech

  2. AbbVie

  3. UCB

  4. Amgen

  5. Novartis Pharmaceuticals Corporation

  6. *Disclaimer: Major Players sorted in no particular order
Janssen Biotech, AbbVie, UCB, Amgen, Novartis Pharmaceuticals Corporation

Global Axial Spondyloarthritis (axSpA) Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?